DBV Technologies Advances Peanut Allergy Patch Trial into Younger Age Group
Event summary
- First participant screened in THRIVE Phase 2 study for VIASKIN® Peanut Patch in infants aged 6–12 months.
- Study aims to assess efficacy and safety over 36 months, with a peanut food challenge at the end.
- Dr. Douglas Mack of McMaster University leads the trial, citing the 'window of opportunity' for early intervention.
- DBV Technologies expands clinical program into the youngest peanut allergy patient population.
The big picture
DBV Technologies is pushing the boundaries of epicutaneous immunotherapy (EPIT) by targeting younger patients, a strategic move that could redefine early intervention in food allergies. The THRIVE study builds on prior positive results in older age groups, positioning DBV to potentially dominate the pediatric peanut allergy market if successful. The focus on infants highlights the company’s commitment to addressing unmet medical needs in a high-stakes, rapidly evolving therapeutic landscape.
What we're watching
- Clinical Efficacy
- Whether early intervention with the VIASKIN® Peanut Patch can alter the trajectory of peanut allergy in infants.
- Regulatory Pathway
- The pace at which DBV Technologies can secure approvals based on THRIVE study outcomes.
- Market Differentiation
- How DBV’s non-invasive approach compares to existing and emerging peanut allergy treatments.
Related topics